IVERIC bio, Inc. (ISEE): Price and Financial Metrics


IVERIC bio, Inc. (ISEE): $22.75

-0.49 (-2.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ISEE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ISEE Stock Price Chart Interactive Chart >

Price chart for ISEE

ISEE Price/Volume Stats

Current price $22.75 52-week high $24.56
Prev. close $23.24 52-week low $8.85
Day low $22.65 Volume 1,139,800
Day high $23.66 Avg. volume 1,798,029
50-day MA $21.44 Dividend yield N/A
200-day MA $16.19 Market Cap 2.75B

IVERIC bio, Inc. (ISEE) Company Bio


IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.


ISEE Latest News Stream


Event/Time News Detail
Loading, please wait...

ISEE Latest Social Stream


Loading social stream, please wait...

View Full ISEE Social Stream

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC BIO INC that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARSIPPANY, N.J., February 02, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees.

Yahoo | February 2, 2023

Insiders who bought IVERIC bio, Inc. (NASDAQ:ISEE) last year must be regretting not buying more as market cap hits US$2.8b

Last week, IVERIC bio, Inc. ( NASDAQ:ISEE ) insiders, who had purchased shares in the previous 12 months were rewarded...

Yahoo | January 24, 2023

RTP gene therapy startup expands pipeline through deal with public biotech

More than a year after launching, a gene therapy company in the Research Triangle Park area has expanded its pipeline through a deal with a public biotech.

Yahoo | January 3, 2023

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

PARSIPPANY, N.J., January 03, 2023--Iveric Bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023.

Yahoo | January 3, 2023

ISEE stock gains on deal to out-license gene therapy candidates (NASDAQ:ISEE)

Clinical-stage biotech IVERIC bio (ISEE), has sold the ownership rights for preclinical stage gene therapy candidates IC-100 and IC-200 to for cash and stock. Read the full story here.

Seeking Alpha | December 28, 2022

Read More 'ISEE' Stories Here

ISEE Price Returns

1-mo 15.13%
3-mo 16.61%
6-mo 74.60%
1-year 51.57%
3-year 223.38%
5-year 698.25%
YTD 6.26%
2022 28.05%
2021 141.97%
2020 -19.46%
2019 615.00%
2018 -61.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6515 seconds.